Agilent Technologies: A “Long Runway” Bet on the Future of Therapeutics Byline: Market Analysis & Forecast When Agilent Technologies CEO Padraig McDonnell talks about a “long runway” in advancing therapeutics, he isn’t making a vague optimism play—he’s pointing directly at one of the most structurally durable growth trends in healthcare. And increasingly, the company is positioning itself to monetize that runway. The News Behind the Narrative McDonnell’s bullish tone comes as Agilent doubles down on its role in drug development infrastructure—particularly in diagnostics, pathology, and therapeutic manufacturing. Recent moves reinforce that thesis: Agilent launched Advanced Therapeutics , consolidating CDMO (contract development & manufacturing) capabilities across North America ( Yahoo Finance ) It is acquiring Biocare Medical for $950M , expanding its footprint in cancer diagnostics and pathology workflows ( Reuters ) The company continues to push into precision oncology and b...